ArticleAnnals of surgical oncology2026
Prognostic Significance of the Uncertain Resection Based on the Extent of Nodal Dissection in Non-small-Cell Lung Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOur objective was to investigate the impact of complete resection (R0)/uncertain resection [R(un)] according to the extent of nodal dissection on overall survival (OS) and disease-free survival (DFS) in patients with non-small-cell lung cancer (NSCLC).
methodsIn total, 3783 patients with primary NSCLC receiving R0/R(un) between 2001 and 2014 were included, and those with the greatest mediastinal lymph node metastasis, operative death, or sublobar resection were excluded. Propensity score matching (PSM) was performed to minimize selection bias. The Kaplan-Meier method and Cox proportional hazards model were applied to assess the prognostic impact of R(un).
resultsR0 patients had better OS and DFS than R(un) patients before and after PSM, with survival differences observed across all clinical and pathological stages (all P < 0.05). However, among patients with tumors ≤2 cm, no significant survival difference was observed (all P > 0.05). OS (P = 0.583) and DFS (P = 0.904) were comparable among P-stage N1 patients with R(un) and p-stage N2 patients with R0. Among patients receiving adjuvant chemotherapy, R(un) patients still had a poorer OS than R0 patients (P = 0.016). In contrast, for patients receiving adjuvant targeted therapy, the OS was comparable between groups (P = 0.577).
conclusionsR(un) is an independent prognostic factor associated with poorer OS and DFS in NSCLC, except in cases involving tumors ≤2 cm. Patients with R(un) should be considered for upstaging to enable more accurate prognosis prediction. Adjuvant targeted therapy may mitigate the adverse prognostic effects of R(un).
Indexed as
Identifiers
41449241What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.